Abbott Plans to Spin Off Its $8.5 Billion Nutrition Business

What happened

Abbott announced on Oct. 21 that it plans to separate its global nutrition business into an independent, publicly traded company. According to MedTech Dive, Abbott shareholders will hold shares in both companies after the separation, which is expected to be completed at the end of 2027, subject to regulatory approval and other conditions.

The nutrition business, which includes Pedialyte, Similac and Ensure, has about $8.5 billion in annual sales.

Transaction and company details

• Structure: A separation of the nutrition business into a stand-alone public company, with Abbott shareholders receiving shares in it.
• Size: About $8.5 billion in annual sales.
• Timeline: Completion expected at the end of 2027.
• Remaining Abbott: Diagnostics, established pharmaceuticals and medical devices, with roughly $42 billion in expected sales.

The announcement came with Abbott’s third-quarter results. Nutrition generated $2.26 billion in revenue in the quarter, up about 5% from a year earlier, while total company sales were $13.01 billion, up 14.5%. Abbott lowered its 2026 sales growth guidance to 6% from a range of 6.5% to 7.5%. The company said the spinoff is not expected to affect 2026 or 2027 guidance, which it plans to provide in January.

“Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition,” said Abbott chief executive Robert Ford. Ford also said the separation would let the remaining Abbott focus on higher-growth markets.

Litigation

The nutrition business has faced lawsuits and a federal investigation tied to a 2022 powdered infant formula recall. MedTech Dive reported that Abbott reached a $385 million settlement with the Department of Justice in September, while other lawsuits remain pending. Ford said resolving the litigation is not a prerequisite for completing the separation.

Analyst views

J.P. Morgan analyst Robbie Marcus said the separation should improve Abbott’s top-line growth and margins. BTIG analyst Marie Thibault noted that nutrition margins are below the corporate average and that infant formula litigation remains an overhang, according to MedTech Dive.

Why it matters for the sector

The move is the latest in a series of portfolio separations among large healthcare conglomerates. MedTech Dive noted that Medtronic recently completed the separation of its diabetes business, MiniMed, and Johnson & Johnson plans to spin out its orthopedics business. Investors have generally favored more focused companies, arguing that conglomerates can obscure the value of faster-growing units.

For Abbott, removing a consumer-oriented business with lower margins would leave a company concentrated in medical devices, diagnostics and branded generics, segments where Abbott has said it sees higher growth.

A stand-alone nutrition company would be one of the larger consumer health businesses on the public market, competing with global food and nutrition groups. Its valuation will depend on growth in adult and pediatric nutrition and on how investors assess remaining litigation risk.

The long timeline, more than a year, is typical for separations of this size, which require new boards, debt structures, regulatory filings and transitional service agreements between the parent and the new company.

Spinoffs can also create costs. The new company will need its own corporate functions, and the parent loses some scale in purchasing and distribution. Companies usually address those issues with transition agreements that run for a period after separation, while investors weigh any lost synergies against the benefits of focus.

What to watch

• Details of the separation structure, leadership and capital allocation for the new nutrition company.
• Developments in infant formula litigation.
• Abbott’s 2027 guidance, expected in January.
• Other diversified healthcare companies weighing similar separations.

This article is for information only and is not investment advice.

Sources: MedTech Dive

How a Corporate Spinoff Typically Unfolds

Separating a business of this size into its own public company involves a long sequence of legal, financial and operational steps. While the specifics will be set out in Abbott’s filings, spinoffs commonly follow a pattern like this:

1. Announcement and planning. The parent sets a target timeline and begins defining which assets, employees, contracts and liabilities belong to each company.
2. Leadership and board. The new company’s management team and independent board are named.
3. Registration. In the United States, the new company files a registration statement, often on Form 10, describing its business, finances and risks.
4. Capital structure. The new company typically arranges its own debt, and it may pay a cash distribution to the parent before separation.
5. Tax confirmation. Many spinoffs are designed to be tax-free to the parent and its shareholders under U.S. tax rules, often supported by a ruling or legal opinion.
6. Record and distribution dates. Shareholders who own parent stock on the record date receive new company shares according to a distribution ratio.
7. Trading begins. The new company lists on an exchange. Shares sometimes trade on a “when-issued” basis shortly before the distribution.

Transition Services and Separation Agreements

A new company rarely has every corporate function ready on day one. Separation agreements typically include:

• Transition services agreements, under which the parent continues to provide functions such as information technology, payroll or logistics for a set period.
• Supply or manufacturing agreements where facilities or production lines are shared.
• Tax matters agreements allocating responsibility for past and future taxes.
• Allocation of liabilities, which defines which company bears legacy obligations, including pending litigation. How such obligations are allocated is often closely watched by investors in both companies.

What Shareholders Should Know

Shareholders generally do not need to take action to receive shares in a spinoff; the distribution happens automatically to holders as of the record date. After separation, each company’s stock trades independently, and the combined value can differ from the parent’s former value. Index funds and other investors may rebalance holdings, which can affect trading in the early weeks.

Questions Readers Ask

Why does a spinoff take more than a year?

Separating systems, contracts, regulatory licenses and employees across many countries is complex, and filings must be prepared and reviewed.

Will product availability change?

Spinoffs are generally designed so that products continue to be made and sold without interruption.

Why might a separated nutrition company be valued differently?

Investors often compare stand-alone businesses with peers in the same industry. A nutrition company would likely be measured against consumer and food-focused groups, while the remaining Abbott would be compared with medical device and diagnostics companies, each with its own typical growth rates and valuation ranges.

What is a distribution ratio?

The number of new company shares a shareholder receives for each parent share held on the record date, announced before the separation.

Are there tax consequences?

Individual circumstances vary. Shareholders should consult a tax adviser or financial professional about their own situation.